{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T08:03:31Z","timestamp":1780041811256,"version":"3.53.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.msard.2025.106616","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T20:17:46Z","timestamp":1752610666000},"page":"106616","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Ponesimod as add-on treatment in patients with active relapsing multiple sclerosis under dimethyl fumarate (POINT): A phase 3, randomized, placebo-controlled clinical trial"],"prefix":"10.1016","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4175-5509","authenticated-orcid":false,"given":"Ludwig","family":"Kappos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Burcklen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"D'Ambrosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Freedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Kubala","family":"Havrdova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Hennessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Hohlfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Larbalestier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Lemle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Lindenstr\u00f8m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Lublin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Montalban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Sidorenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Till","family":"Sprenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Vaclavkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Wuerfel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Pozzilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106616_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105009","article-title":"Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: pathogenesis, risk of infection, and disease management","volume":"79","author":"Alvarez","year":"2023","journal-title":"Mult. Scler Relat. Disord."},{"key":"10.1016\/j.msard.2025.106616_bib0002","article-title":"Biogen European Union Risk Management Plan for Tecfidera (2022,October 25)","year":"2022","journal-title":"Europe. Union (EU) Risk Management Plan (RMP) TecfideraTM (Dimethyl Fumarate)"},{"key":"10.1016\/j.msard.2025.106616_bib0003","article-title":"TecfideraTM (dimethyl fumarate) [package insert]. U.S","year":"2024","journal-title":"Food Drug Administrat. Website"},{"issue":"3","key":"10.1016\/j.msard.2025.106616_bib0004","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40265-024-02011-w","article-title":"Drugs targeting CD20 in multiple sclerosis: pharmacology, efficacy, safety, and tolerability","volume":"84","author":"Carlson","year":"2024","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.msard.2025.106616_bib0005","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1093\/rheumatology\/kei031","article-title":"A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal","volume":"44","author":"Choy","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.msard.2025.106616_bib0006","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/B978-0-444-52001-2.00014-5","article-title":"The clinical course of multiple sclerosis","volume":"122","author":"Confavreux","year":"2014","journal-title":"Handb. Clin. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2025.106616_bib0008","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1177\/2040622315617354","article-title":"Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases","volume":"7","author":"D'Ambrosio","year":"2016","journal-title":"Ther. Adv. Chronic. Dis."},{"key":"10.1016\/j.msard.2025.106616_bib0009","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1362629","article-title":"A metformin add-on clinical study in multiple sclerosis to evaluate brain remyelination and neurodegeneration (MACSiMiSE-BRAIN): study protocol for a multi-center randomized placebo controlled clinical trial","volume":"15","author":"De Keersmaecker","year":"2024","journal-title":"Front Immunol."},{"issue":"10","key":"10.1016\/j.msard.2025.106616_bib0010","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/acn3.114","article-title":"Outcome and survival of asymptomatic PML in natalizumab-treated MS patients","volume":"1","author":"Dong-Si","year":"2014","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"Suppl 3","key":"10.1016\/j.msard.2025.106616_bib0011","first-page":"P17","article-title":"Oral teriflunomide plus glatiramer acetate in relapsing multiple sclerosis","volume":"13","author":"Freedman","year":"2011","journal-title":"Int. J. MS Care."},{"issue":"15 Supplement","key":"10.1016\/j.msard.2025.106616_bib0012","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1212\/WNL.94.15_supplement.1752","article-title":"Long-term efficacy and safety of Ponesimod, an oral S1P1 receptor modulator: results from randomized phase II core and extension studies in relapsing-remitting multiple sclerosis (1752)","volume":"94","author":"Freedman","year":"2020","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.msard.2025.106616_bib0013","doi-asserted-by":"crossref","first-page":"e762","DOI":"10.1212\/WNL.0000000000200606","article-title":"Long-term treatment with Ponesimod in relapsing-remitting multiple sclerosis: results from randomized phase 2b core and extension studies","volume":"99","author":"Freedman","year":"2022","journal-title":"Neurology"},{"issue":"23","key":"10.1016\/j.msard.2025.106616_bib0014","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1212\/WNL.0b013e318258f7d4","article-title":"Teriflunomide added to interferon-beta in relapsing multiple sclerosis: a randomized phase II trial","volume":"78","author":"Freedman","year":"2012","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2025.106616_bib0015","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/1352458520949158","article-title":"Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients","volume":"28","author":"Jordan","year":"2022","journal-title":"Multiple Sclerosis J."},{"key":"10.1016\/j.msard.2025.106616_bib0016","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2021.0405","article-title":"Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: a randomized clinical trial","author":"Kappos","year":"2021","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.msard.2025.106616_bib0017","doi-asserted-by":"crossref","first-page":"e517","DOI":"10.1212\/NXI.0000000000000517","article-title":"Disease-modifying therapies alter gut microbial composition in MS","volume":"6","author":"Katz Sand","year":"2019","journal-title":"Neurol Neuroimmunol. Neuroinflamm."},{"issue":"Suppl 5","key":"10.1016\/j.msard.2025.106616_bib0018","doi-asserted-by":"crossref","first-page":"v46","DOI":"10.1007\/s00415-005-5008-1","article-title":"Multiple sclerosis trial designs for the 21st century: building on recent lessons","volume":"252","author":"Lublin","year":"2005","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2025.106616_bib0019","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection risks among patients with multiple sclerosis treated with Fingolimod, Natalizumab, Rituximab, and injectable therapies","volume":"77","author":"Luna","year":"2020","journal-title":"Jama Neurol."},{"issue":"2","key":"10.1016\/j.msard.2025.106616_bib0020","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/ene.13536","article-title":"ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis","volume":"25","author":"Montalban","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2025.106616_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102988","article-title":"Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases","volume":"52","author":"Oksbjerg","year":"2021","journal-title":"Mult. Scler. Relat. Disord"},{"issue":"11","key":"10.1016\/j.msard.2025.106616_bib0022","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1136\/jnnp-2013-307282","article-title":"Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial","volume":"85","author":"Olsson","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"issue":"2","key":"10.1016\/j.msard.2025.106616_bib0023","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1124\/jpet.110.176487","article-title":"The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation","volume":"337","author":"Piali","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.msard.2025.106616_bib0024","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"issue":"3\u20134","key":"10.1016\/j.msard.2025.106616_bib0025","first-page":"22","article-title":"Therapeutic potential of Ponesimod alone and in combination with dimethyl fumarate in experimental models of multiple sclerosis","volume":"16","author":"Pouzol","year":"2019","journal-title":"Innov. Clin. Neurosci."},{"issue":"10","key":"10.1016\/j.msard.2025.106616_bib0026","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1111\/ene.15988","article-title":"Progressive multifocal leukoencephalopathy in a patient with relapsing multiple sclerosis treated with ocrelizumab: a case report","volume":"30","author":"Puig-Casadevall","year":"2023","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2025.106616_bib0007","doi-asserted-by":"crossref","unstructured":"Riboni-Verri, G., E McMurran, C., Mukherjee, T. et al., The Cambridge Centre for Myelin Repair trial Two (CCMR Two): a trial protocol for a phase 2a, randomised, double-blind, placebo-controlled clinical trial of the ability of the combination of metformin and clemastine to promote remyelination in people with relapsing-remitting multiple sclerosis already on disease-modifying therapy.18 June 2025, PREPRINT (Version 1) available at Research Square https:\/\/doi.org\/10.21203\/rs.3.rs-6197547\/v1.","DOI":"10.1186\/s13063-025-09254-2"},{"issue":"2","key":"10.1016\/j.msard.2025.106616_bib0027","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.msard.2025.106616_bib0028","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1124\/jpet.111.190132","article-title":"Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway","volume":"341","author":"Scannevin","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.msard.2025.106616_bib0029","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1007\/s00415-021-10910-1","article-title":"Progressive multifocal leukoencephalopathy and sphingosine 1-phosphate receptor modulators used in multiple sclerosis: an updated review of literature","volume":"269","author":"Sriwastava","year":"2022","journal-title":"J. Neurol."},{"issue":"760","key":"10.1016\/j.msard.2025.106616_bib0030","article-title":"B and T cells driving multiple sclerosis: identity, mechanisms and potential triggers","volume":"11","author":"van Langelaar","year":"2020","journal-title":"Front Immunol."},{"issue":"4","key":"10.1016\/j.msard.2025.106616_bib0031","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00109-019-01761-5","article-title":"Insight into the mechanism of action of dimethyl fumarate in multiple sclerosis","volume":"97","author":"Yadav","year":"2019","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.msard.2025.106616_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101459","article-title":"Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines","volume":"37","author":"Yamout","year":"2020","journal-title":"Mult. Scler Relat. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482500358X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482500358X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T07:22:12Z","timestamp":1780039332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482500358X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":32,"alternative-id":["S221103482500358X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106616","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ponesimod as add-on treatment in patients with active relapsing multiple sclerosis under dimethyl fumarate (POINT): A phase 3, randomized, placebo-controlled clinical trial","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106616","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106616"}}